Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Baxter
Johnson and Johnson
Harvard Business School
McKinsey

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022577

See Plans and Pricing

« Back to Dashboard

NDA 022577 describes VIREAD, which is a drug marketed by Gilead Sciences Inc and is included in two NDAs. It is available from three suppliers. Additional details are available on the VIREAD profile page.

The generic ingredient in VIREAD is tenofovir disoproxil fumarate. There are forty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the tenofovir disoproxil fumarate profile page.
Summary for 022577
Tradename:VIREAD
Applicant:Gilead Sciences Inc
Ingredient:tenofovir disoproxil fumarate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 022577
Suppliers and Packaging for NDA: 022577
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIREAD tenofovir disoproxil fumarate POWDER;ORAL 022577 NDA Gilead Sciences, Inc. 61958-0403 61958-0403-1 1 BOTTLE, PLASTIC in 1 CARTON (61958-0403-1) > 60 g in 1 BOTTLE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORALStrength40MG/SCOOPFUL
Approval Date:Jan 18, 2012TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 11, 2021
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Jun 11, 2022
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY

Expired US Patents for NDA 022577

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead Sciences Inc VIREAD tenofovir disoproxil fumarate POWDER;ORAL 022577-001 Jan 18, 2012   Start Trial   Start Trial
Gilead Sciences Inc VIREAD tenofovir disoproxil fumarate POWDER;ORAL 022577-001 Jan 18, 2012   Start Trial   Start Trial
Gilead Sciences Inc VIREAD tenofovir disoproxil fumarate POWDER;ORAL 022577-001 Jan 18, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Mallinckrodt
Boehringer Ingelheim
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.